Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.
about
Statin Therapy: Review of Safety and Potential Side EffectsStatins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represAnalysis of National Pharmacovigilance Data Associated with Statin Use in Korea.2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy ModelAtorvastatin inhibits insulin synthesis by inhibiting the Ras/Raf/ERK/CREB pathway in INS-1 cellsEffect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis.A medication review and deprescribing method for hospitalised older patients receiving multiple medications.Statin therapy across the lifespan: evidence in major age groups.Discontinuation of Statins: What Are the Risks?Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men.Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies.Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care.Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity-Adjusted Analysis.Harmful impact of morphine use in acute heart failure.Statins for Primary Prevention in Older Adults: An Unresolved Conundrum.Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).2016 European Guidelines on cardiovascular disease prevention in clinical practice
P2860
Q28072883-97B64888-429C-4DEA-86F1-4437048E740DQ33675377-239D745E-D34D-4073-9901-9CDC6767C098Q34046881-2165CDFF-6E17-415E-9817-4E3D5825F70AQ36370933-7C50B14C-2F90-4827-952B-49BE49C5E311Q37240391-3C5A7E7D-E74A-449E-AC33-095B049CCF59Q37265528-E4DC3BC1-4B7E-408D-A49B-55814964C960Q37605825-A0584863-C827-48A4-8F1A-62103ECDC90EQ38376542-D0D249AB-D1EE-498F-B715-2F8682BB9364Q38561391-49BD0C2C-3AB4-43DE-B1AE-3CDF0DE8D3AAQ38589894-4BD4460F-B8AB-433A-9CCC-2A314C4DCF8FQ38660929-690B08F8-AC1F-4F8F-9B4E-B94FB3AF92F8Q38843485-169315DC-D9A1-4E27-83BE-042D9CC05784Q39456483-CBB78A67-C4B2-4859-91C4-F8037475FA92Q40047849-D94EE4C3-392B-4A6E-9A97-557D6F43FCBDQ40107412-6AFE0CDD-4674-405A-98B2-3358D0E8F351Q40131379-3C51C8E8-6135-4BE5-BF53-3CBE5F50B842Q40694127-D0BA2EBF-78BC-40BB-9C12-57E25AA55BA8Q40704753-F6492AAD-03C2-4B37-A315-C9BB273960AAQ42342020-A1AB753E-9908-4673-99C9-D7A2842BE9A6Q50158643-676F6EA5-13E7-4450-A32C-DEF05C47A1F5Q55431904-A5F94605-601E-410B-B2F1-25265526017BQ55476982-FF70A2A7-33DF-47B7-B90F-F78DAC31E363Q56991525-E82371A8-55D5-45E3-BA8F-57A26B808940
P2860
Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness and populat ...... or older in the United States.
@ast
Cost-effectiveness and populat ...... or older in the United States.
@en
type
label
Cost-effectiveness and populat ...... or older in the United States.
@ast
Cost-effectiveness and populat ...... or older in the United States.
@en
prefLabel
Cost-effectiveness and populat ...... or older in the United States.
@ast
Cost-effectiveness and populat ...... or older in the United States.
@en
P2093
P2860
P356
P1476
Cost-effectiveness and populat ...... or older in the United States.
@en
P2093
David Guzman
David Heller
Divya Thekkethala
Lee Goldman
Mark J Pletcher
Michelle C Odden
Pamela G Coxson
P2860
P304
P356
10.7326/M14-1430
P407
P577
2015-04-01T00:00:00Z